Colgate/Vipont merger
Executive Summary
Hart-Scott-Rodino waiting period extended by Federal Trade Commission, which requests additional information on the oral care businesses of Colgate-Palmolive and Vipont Pharmaceutical, Colgate said Nov. 30. Both firms plan to comply "as promptly as possible." Proposed merger would combine Colgate's $ 1 bil. worldwide oral care business with Vipont's $ 37-$ 39 mil. franchise ("The Pink Sheet" Nov. 13, T&G-12). Colgate estimates that it holds a 30%-32% share of the dentifrice market while Vipont controls a 1.5% stake.
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: